Jiangsu Kanion Pharma has transferred the global ex-China rights for three small molecule oncology drug candidates to a newly formed California startup, NewGen Therapeutics, in exchange for a minority position in NewGen. The CEO of Kanion USA, Wang Shen, is a co-founder and VP of R&D at NewGen. In China, Kanion is known mainly as a TCM company. More details.... Stock Symbol: (SHA: 600557) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});